Traditional and modern management strategies for rheumatoid arthritis

Clin Chim Acta. 2021 Jan:512:142-155. doi: 10.1016/j.cca.2020.11.003. Epub 2020 Nov 11.

Abstract

Rheumatoid arthritis (RA) is a serious disorder of the joints affecting 1 or 2% of the population aged between 20 and 50 years worldwide. RA is the foremost cause of disability in developing and Western populations. It is an autoimmune disease-causing inflammation and pain involving synovial joints. Pro-inflammatory markers, including cytokines, such as interleukin -1 (IL-1), IL-6, IL-7, IL-8, and tumor necrosis factor-α (TNF-α) are involved in RA. RA treatment involves TNF-α blockade, B cell therapy, IL-1 and IL-6 blockade, and angiogenesis inhibition. Synthetic drugs available for the treatment of RA include disease-modifying anti-rheumatic drugs (DMARD), such as cyclophosphamide, sulfasalazine, methotrexate, nonsteroidal anti-inflammatory drugs (NSAIDs), and intramuscular gold. These agents induce adverse hepatorenal effects, hypertension, and gastric ulcers. We found that patients diagnosed with chronic pain, as in RA, and those refractory to contemporary management are most likely to seek traditional medicine. Approximately 60-90% of patients with arthritis use traditional medicines. Therefore, the efficacy and safety of these traditional medicines need to be established. The treatment for RA entails a comprehensive multidisciplinary strategy to reduce pain and inflammation and to restore the activity of joints. The potential medicinal plants exhibiting anti-arthritic and anti-rheumatic pharmacological activity are reviewed here.

Keywords: Anti-arthritic potential; Management of arthritis; Rheumatoid arthritis; Traditional medicines.

Publication types

  • Review

MeSH terms

  • Adult
  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Rheumatoid* / drug therapy
  • Humans
  • Interleukin-1
  • Methotrexate / therapeutic use
  • Middle Aged
  • Tumor Necrosis Factor-alpha
  • Young Adult

Substances

  • Antirheumatic Agents
  • Interleukin-1
  • Tumor Necrosis Factor-alpha
  • Methotrexate